Skip to content

management of diabetic dyslipidemia through ayurveda intervention

Efficacy of Navayasa Lauha, Gomutra Haritaki and Dhanvantara Ghrita in management of diabetic dyslipidemia (Prameha): An open labeled randomized standard controlled clinical trial - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/086703
Enrollment
100
Registered
2025-05-09
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E782- Mixed hyperlipidemia

Interventions

None listed

Sponsors

Institute of Teaching and Research in Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Participants having age between 18 60 years of either gender. Participant fulfilling diagnostic criteria. BMI- 18.5- 34.9 kg/m2 (Normal, overweight, Obese class I) Newly diagnosed cases of diabetes as well as dyslipidaemia. Previously diagnosed cases, in spite of taking hypolipidemic drugs fulfilling diagnostic criteria can be selected after giving proper washout period. Participants willing to give their consent to participate in the study.

Exclusion criteria

Exclusion criteria: age below 18 years and above 60 years Lipid profile with very high level (S.Triglyceride more than 499 mg/dl, S.LDL more than 190 mg/dl) BMI- below 18.5 and above 34.9 kg/m2 Participant suffering from type 1 DM or participant taking insulin Injection. Poorly controlled HTN (Systolic BP more than160 mmHg, Diastolic BP more than 100 mmHg), known cases of Hypothyroidism (TSH more than 10). Drug induced Hyperlipidemia. Participant having concomitant diseases like ischemic heart disease (IHD), Acute Kidney Injury (AKI), chronic kidney disease (CKD). Alcoholics or Drug abuse participants. Participant on oral contraceptives, pregnant female or lactating mother. Participant having any psychiatric illness e.g., bipolar disorder, schizophrenia, acute anxiety and depression.

Design outcomes

Primary

MeasureTime frame
Reduction in the levels of Sr. Triglycerides and Sr. LDL Increase in Sr. HDL level.Timepoint: 12 weeks

Secondary

MeasureTime frame
Reduction in the levels of Sr. Triglycerides and Sr. LDL Increase in Sr. HDL level. Reduction in weight and BMI. Reduction in the levels FBS & PPBS Reduction in Apolipoprotein B. Increase in Serum C-peptide level Reduction in HS-CRP Reduction in the Atherosclerotic Cardiovascular Diseases (ASCVD) risk score and QRISK Score 3.Timepoint: 12 weeks

Countries

India

Contacts

Public ContactDr Mandip Goyal

Institute of Teaching and Research in Ayurveda, Jamnagar

mandipgoyal@itra.edu.in9427572306

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026